SAGE Therapeutics confirms receipt of acquisition proposal from Biogen (BIIB)
- Sage Therapeutics, Inc. (SAGE) confirmed that Biogen Inc. (BIIB) has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share.
- Consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Sage Board of Directors will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders.
No comments:
Post a Comment